Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats

Investigative Ophthalmology and Visual Science

Volumn 45, Issue 8, 2004, Pages 2497-2502

  Chi, Zai Long ^a   Hayasaka, Seiji ^a   Zhang, Xue Yun ^a   Hayasaka, Yoriko ^a   Cui, Hu Shan ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NITRATE; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; SYNAPTOTAGMIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CILIARY BODY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; UVEITIS;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; AQUEOUS HUMOR; CILIARY BODY; E-SELECTIN; ESCHERICHIA COLI; IMMUNOENZYME TECHNIQUES; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-6; IRIS; LIPOPOLYSACCHARIDES; MALE; NF-KAPPA B; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROLIPRAM; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS, ANTERIOR;

EID: 3242880720     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.03-1373     Document Type: Article

References (28)

1. Rosenbaum JT, McDevitt HO, Guss RB, Egbert PR. Endotoxin-induced uveitis in rats as a model for human disease. Nature. 1980;286:611-613.
2. Hoekzema R, Verhagen C, van Haren M, Kijlstra A. Endotoxin-induced uveitis in the rat: the significance of intraocular interleukin-6. Invest Ophthalmol Vis Sci. 1992;33:532-539.
3. de Vos AF, van Haren MAC, Verhagen C, Hoekzema R, Kijlstra A. Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci. 1994;35:1100-1106.
4. Suzuma I, Mandai M, Suzuma K, Ishida K, Tojo SJ, Honda Y. Contribution of E-selectin to cellular infiltration during endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 1998;39:1620-1630.
5. Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-α) biosynthesis in alveolar epithelial cells. J Pharmacol Exp Ther. 2002;300:559-566.
6. Lang CH, Silvis C, Deshpande N, Nystrom G, Frost RA. Endotoxin stimulates in vivo expression of inflammatory cytokines tumor necrosis factor alpha, interleukin-1[beta],-6, and high-mobility-group protein-1 in skeletal muscle. Shock. 2003;19:538-546.
7. Goureau O, Bellot J, Thillaye B, Courtois Y, de Kozak Y. Increased nitric oxide production in endotoxin-induced uveitis: reduction of uveitis by an inhibitor of nitric oxide synthase. J Immunol. 1995;154:6518-6523.
8. Jacquemin E, de Kozak Y, Thillaye B, Courtois Y, Goureau O. Expression of inducible nitric oxide synthase in the eye from endotoxin-induced uveitis rats. Invest Ophthalmol Vis Sci. 1996;37:1187-1196.
9. Ohgami K, Shiratory K, Kotake S, Nishida T, Mizuki N, Yazawa K, Ohno S. Effects of astaxanthin on hpopolysaccharide-induced inflammation in vitro and in vivo. Invest Ophthalmol Vis Sci. 2003;44:2694-2701.
10. Nathan CF, Xie F. Regulation of biosynthesis of nitric oxide. J Biol Chem. 1994;269:13725-13728.
11. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 1994;12:141-179.
12. Robicsek SA, Blanchard DK, Djeu JY, Krzanowski JJ, Szentivanyi A, Polson JB. Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem Pharmacol. 1991;42:869-877.
13. Godfrey RW, Manzi RM, Gennaro DE, Haffstein ST. Phospholipid and arachidonic acid metabolism in zymosan-stimulated human monocytes: modulation by cAMP. J Cell Physiol. 1987;131:384-392.
14. Nielson CP, Vestal RE, Sturm RJ, Heaslip R, Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol. 1990;86:801-808.
15. Souness JE, Carter CM, Diocee BK, Hassall GA, Wood LJ, Turner NC. Characterization of guinea-pig eosinophil phosphodiesterase activity: assessment of its involvement in regulating superoxide generation. Biochem Pharmacol. 1991;42:937-945.
16. Teixeira MM, Rossi AG, Williams TJ, Hellewell PG. Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig. Br J Pharmacol. 1994;112:332-340.
17. Klemm P, Harris HJ, Perretti M. Effect of rolipram in a murine model of acute inflammation: comparison with the corticoid dexamethasone. Eur J Pharmacol. 1995;281:69-74.
18. Buttini M, Mir A, Appel K, et al. Lipopolysaccharide induces expression of tumor necrosis factor alpha in rat brain: inhibition by methylprednisolone and by rolipram. Br J Pharmacol. 1997;122:1483-1489.
19. Ross SE, Williams RO, Mason LJ, et al. Suppression of TNF-α expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol. 1997;159:6253-6259.
20. Xu H, Strassmann G, Chan CC, et al. Protective effect of the type 4 phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity. Invest Opthalmol Vis Sci. 1999;40:942-950.
21. Blease K, Burke-Gaffney A, Hellewell PG. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cell by inhibition of phosphodiesterase 3 and 4. Br J Pharmacol. 1998;124:229-237.
22. Sanz MJ, Alvarez A, Piqueras L, et al. Rolipram inhibits leukocyte-endothelial cell interaction in vivo through P- and E-selectin down-regulation. Br J Pharmacol. 2002;135:1872-1881.
23. Bodon D, Breulet M, Gerard-Vandenhove MA, et al. Is phosphodiesterase inhibition a new mechanism of antidepressant action? - a double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur Arch Psychiatry Neurol Sci. 1988;238:2-6.
24. Bradford MM. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
25. Wachtel H. Characteristic behavioral alterations in rats induced by rolipram and other selective adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitors. Psychopharmacology. 1982;77:309-316.
26. Ollivier V, Parry GCN, Cobb RR, de Prost D, Mackman N. Elevated cyclic AMP inhibits NF-kb-mediated transcription in human monocytic cells and endothelial cells. J Biol Chem. 1996;271:20828-20835.
27. Dutta P, Ryan DE, Tabrizchi R. The influence of phosphodiesterase inhibitor, rolipram, on hemodynamics in lipopolisaccharide-treated rats. Jpn J Pharmacol. 2001;85:241-249.
28. Lieb K, Engels S, Fiebich BL. Inhibition of LPS-induced iNOS and NO synthesis in primary rat microglial cells. Neurochem Int. 2003;42:131-137.